Acadia Pharma GAAP EPS of $0.16 beats by $0.03, revenue of $264.6M beats by $2.6M
Source: SeekingAlpha
2025-08-06 16:18:46 ET
More on Acadia Pharma
- Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
- ACADIA Pharmaceuticals: Advancing On Several Fronts
- Acadia gets court approval related to Nuplazid patent
- Acadia Pharmaceuticals jumps after win in patent suit over Nuplazid
- Seeking Alpha’s Quant Rating on Acadia Pharma
Read the full article on Seeking Alpha
For further details see:
Acadia Pharma GAAP EPS of $0.16 beats by $0.03, revenue of $264.6M beats by $2.6M
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD
ACAD Trading
-1.34% G/L:
$21.025 Last:
573,736 Volume:
$21.41 Open:
ACAD Latest News
March 12, 2026 04:05:00 pm
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 03, 2026 04:05:00 pm
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
ACAD Stock Data
$3,864,112,700
124,348,635
0.05%
128
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
